NKGN VS SCYX Stock Comparison

Performance

NKGN
10/100

NKGN returned -53.87% in the last 12 months. Based on SPY's performance of 9.73%, its performance is below average giving it a score of 10 of 100.

SCYX
12/100

SCYX returned -29.46% in the last 12 months. Based on SPY's performance of -21.29%, its performance is below average giving it a score of 11 of 100.

Volatility

NKGN
10/100

NKGN has had a lower than average amount of volatility over the last 12 months giving it a score of 10 of 100.

SCYX
41/100

SCYX has had a lower than average amount of volatility over the last 12 months giving it a score of 41 of 100.

Analyst Price Targets

NKGN

"Analyst Price Targets" not found for NKGN

SCYX
82/100

7 analysts offer 12-month price targets for SCYX. Together, they have an average target of 8, the most optimistic target put SCYX at 8 within 12-months and the most pessimistic has SCYX at 8.

Sentiment

NKGN

"Sentiment" not found for NKGN

SCYX
64/100

SCYX had a bullish sentiment score of 64.24% across Twitter and StockTwits over the last 12 months. It had an average of 12.74 posts, 5.98 comments, and 18.77 likes per day.

Technicals

NKGN

"Technicals" not found for NKGN

SCYX
11/100

SCYX receives a 10 of 100 based on 14 indicators. 1 are bullish, 12 are bearish.

Earnings

NKGN

"Earnings" not found for NKGN

SCYX
27/100

SCYX has missed earnings 4 times in the last 20 quarters.

Profit

NKGN

"Profit" not found for NKGN

SCYX
22/100

Out of the last 20 quarters, SCYX has had 5 profitable quarters and has increased their profits year over year on 3 of them.

All score calculations are broken down here to help you make more informed investing decisions

NKGen Biotech, Inc. Common Stock Summary

Nasdaq / NKGN

Healthcare

Biotechnology

Graf Acquisition Corp. IV does not have significant operations. It focuses on effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or other business combination with one or more businesses. Graf Acquisition Corp. IV was incorporated in 2021 and is based in The Woodlands, Texas.

SCYNEXIS, Inc. Summary

Nasdaq / SCYX

Healthcare

Drug Manufacturers - Specialty & Generic

SCYNEXIS, Inc., a biotechnology company, develops products for the treatment fungal infections in the United States. It offers BREXAFEMME (ibrexafungerp tablets) for the treatment of vulvovaginal candidiasis (VVC). The company is developing its lead product candidate, Ibrexafungerp, as a novel oral and intravenous drug for the treatment of various fungal infections, including recurrent VVC, invasive aspergillosis, invasive candidiasis, and refractory invasive fungal infections; and ibrexafungerp that has completed Phase 3 CANDLE study for the prevention of recurrent (VVC). It has research collaborations with Merck Sharp & Dohme Corp., Hansoh (Shanghai) Health Technology Co., Ltd., Jiangsu Hansoh Pharmaceutical Group Company Limited, and R-Pharm, CJSC to develop and commercialize rights for ibrexafungerp. The company was formerly known as SCYNEXIS Chemistry & Automation, Inc. and changed its name to SCYNEXIS, Inc. in June 2002. SCYNEXIS, Inc. was incorporated in 1999 and is headquartered in Jersey City, New Jersey.

Power up your portfolio